Luis A. Chiriboga

Biosketch / Results /

Luis Chiriboga

Research Assistant Professor, Department of Pathology

Contact Info

Address
522 First Avenue
New York, NY 10016

646/501-6934
Luis.Chiriboga@nyumc.org


Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells
Billerbeck, Eva; Mommersteeg, Michiel C; Shlomai, Amir; Xiao, Jing W; Andrus, Linda; Bhatta, Ankit; Vercauteren, Koen; Michailidis, Eleftherios; Dorner, Marcus; Krishnan, Anuradha; Charlton, Michael R; Chiriboga, Luis; Rice, Charles M; de Jong, Ype P. Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. Journal of hepatology. 2016 May 2;65(2):334-343 (2101282)

Endothelin-1 in the tumor microenvironment correlates with melanoma invasion
Chiriboga, Luis; Meehan, Shane; Osman, Iman; Glick, Michael; de la Cruz, Gelo; Howell, Brittny S; Friedman-Jimenez, George; Schneider, Robert J; Jamal, Sumayah. Endothelin-1 in the tumor microenvironment correlates with melanoma invasion. Melanoma research. 2016 Jun ;26(3):236-244 (1929752)

NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma
Panaccione, Alex; Chang, Michael T; Carbone, Beatrice E; Guo, Yan; Moskaluk, Christopher A; Virk, Renu K; Chiriboga, Luis; Prasad, Manju L; Judson, Benjamin; Mehra, Saral; Yarbrough, Wendell G; Ivanov, Sergey V. NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma. Clinical cancer research. 2016 Apr;22(8):2083-2095 (2098162)

A novel CXCR4 antagonist interferes with antivascular endothelial growth factor therapy-induced glioma dissemination
Gagner, J -P; Sarfraz, Y; Alotaibi, F M; Ortenzi, V; Tayyib, A T; Chiriboga, L A; Douglas, G J; Chevalier, E; Romagnoli, B; Tuffin, G; Dembowsky, K; Zagzag, D. A novel CXCR4 antagonist interferes with antivascular endothelial growth factor therapy-induced glioma dissemination [Meeting Abstract]. Cancer research. 2015 01 Dec 2015;75(23):- (2015072)

Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High Risk Melanoma
Lubong Sabado, Rachel; Pavlick, Anna; Gnjatic, Sacha; Cruz, Crystal M; Vengco, Isabelita; Hasan, Farah; Spadaccia, Meredith; Darvishian, Farbod; Chiriboga, Luis; Holman, Rose Marie; Escalon, Juliet; Muren, Caroline; Escano, Crystal; Yepes, Ethel; Sharpe, Dunbar; Vasilakos, John P; Rolnitzky, Linda; Goldberg, Judith D; Mandeli, John P; Adams, Sylvia; Jungbluth, Achim A; Pan, Linda; Venhaus, Ralph; Ott, Patrick A; Bhardwaj, Nina. Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High Risk Melanoma. Cancer immunology research. 2015 Jan 29;3(3):278-287 (1447932)